Navlimetostat
Sponsors
Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb, M.D. Anderson Cancer Center, Daniel Nussbaum, M.D.
Conditions
Advanced and/or Metastatic Solid Tumors with Homozygous MTAP DeletionHealthy Female AdultsHealthy Female ParticipantsHealthy ParticipantsNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)
Phase 1
A Phase 1 Study of Navlimetostat Tablet Formulations
RecruitingNCT07544628
Start: 2026-04-27End: 2026-11-02Target: 64Updated: 2026-10-07
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
RecruitingNCT07579221
Start: 2026-07-16End: 2031-08-01Target: 17Updated: 2026-09-25
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Not yet recruitingNCT07777133
Start: 2026-09-16End: 2026-12-05Target: 6Updated: 2026-08-20
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
RecruitingNCT07800897
Start: 2026-08-31End: 2027-03-25Target: 80Updated: 2026-10-05
A Phase Ib/II Open Label Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer
Not yet recruitingNCT07905131
Start: 2027-01-15End: 2031-06-30Target: 18Updated: 2026-10-29
Phase 2
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Active, not recruitingNCT07076121
Start: 2025-10-23End: 2029-05-03Target: 470Updated: 2026-06-03
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
Not yet recruitingCTIS2025-524285-18-00
Target: 67Updated: 2026-07-08